Ixifi Indications/Uses

Rheumatoid Arthritis (RA): IXIFI, in combination with methotrexate (MTX), is indicated for: The reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease-modifying drugs, including MTX, has been inadequate.
Adult patients with severe, active and progressive disease not previously treated with MTX or other disease-modifying anti-rheumatic drugs (DMARDs).
In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see Pharmacology: Pharmacodynamics under Actions).
Crohn's Disease: IXIFI is indicated for: Treatment of moderately to severely, active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Treatment of fistulizing Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Pediatric Crohn's Disease: IXIFI is indicated for: Treatment of severe, active Crohn's disease, in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy.
Ulcerative Colitis: IXIFI is indicated for: Treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Pediatric Ulcerative Colitis: IXIFI is indicated for: Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy.
Ankylosing Spondylitis: IXIFI is indicated for: Treatment of ankylosing spondylitis, in adult patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy.
Psoriatic Arthritis: IXIFI, in combination with MTX, is indicated for: Treatment of active and progressive psoriatic arthritis in adult patients who have responded inadequately to DMARDs.
Psoriasis: IXIFI is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see Pharmacology: Pharmacodynamics under Actions).